Monia Brett P 4

What Happened

• Monia Brett, CEO of Ionis Pharmaceuticals, had 122,214 performance-based restricted stock units (PRSUs) vest on 2026-01-29 (acquired at $0).
• The next day (2026-01-30) she disposed of 62,970 shares in open-market sales for aggregate proceeds of $5,208,979 (weighted average price $82.72).

Key Details

• Award (A): 122,214 shares vested on 2026-01-29; acquisition price reported $0.00.
• Sale (S): 62,970 shares sold on 2026-01-30; weighted avg price $82.72; prices ranged $82.26–$82.925 (footnote).
• Total proceeds from the sales: $5,208,979.
• Footnote F1: The 122,214 shares were PRSUs for a grant reported Jan 18, 2023; Compensation Committee certified performance at 167.27% of target (payout range 0–200%).
• Footnote F2: The sale price shown is a weighted average; the reporting person will provide per-price breakdown on request.
• Shares owned after the transactions: not disclosed in the provided Form 4 excerpt.
• Filing timeliness: Form 4 filed 2026-02-02 for transactions on Jan 29–30; this filing is within the SEC two-business-day reporting window (timely).

Context

• The 122,214 shares were a performance-based award that vested (not a cash purchase); the subsequent sale was an open-market disposition of a portion of those shares.
• This reporting is factual—vesting and a follow-up sale—rather than an explicit statement of insider sentiment.